Amniotic Membrane Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Amniotic Membrane Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The amniotic membrane market studied is estimated to register a CAGR of 10.5% over the forecast period (2022-2027).

The outbreak of the COVID-19 pandemic impacted the amniotic membrane market significantly. Most elective surgeries were suspended globally to mitigate the spread of COVID-19. Due to delayed surgeries and the closure of elective procedures, most of the end-users witnessed the expiry of their stock of amniotic membrane coinciding with the COVID-19 outbreak. This impacted the market negatively. However, the growth of the market studied was balanced by the increasing need for surgeries and ophthalmic procedures accompanied by increased childbirth globally. An article “Amniotic membrane harvesting during COVID-19 pandemic” published in March 2021 suggested that whether amniotic membranes from infected donors carry COVID-19 is unknown, and the probability of vertical transmission is of low risk and not definite. Hence, followed by several research studies, the usage of amniotic membrane significantly increased in ophthalmic centers. Thus, the covid-19 pandemic is anticipated to have a positive impact on the market studied.

Factors such as a rise in the number of accident and trauma cases, increasing awareness about the benefits offered by an amniotic membrane, and rising research on stem cell biology and regenerative medicine are the major driving factors for the studied market growth. Additionally, the growing number of surgeries performed and rising expenditure on research and development (R&D) in the field of stem cells and regenerative medicine are also some of the key factors driving the overall market.

The studied market growth can be attributed to the rise in the number of accident, trauma, and burn injury cases and increasing awareness about the benefits offered by the amniotic membrane. Burn injuries represent a significant disease burden on the world population, with nearly 9 million injuries and an estimated 120,000–180,000 deaths annually, as mentioned in the research paper “Burn injury prevention in low- and middle- income countries (LMICs): scoping systematic review” published in October 2021. According to the above-mentioned research, almost 18 million disability-adjusted life years (DALYs) can be accounted for burns, with a disproportionate 90% of this burden which is borne by LMICs. Also, in Bangladesh, Colombia, Egypt, and Pakistan, burn injuries account for up to 18% of permanent disabilities as per the same research above. The amniotic membrane is commonly used to treat up to second-degree burn wounds. Thus, the rising burden of burn injuries globally is predicted to drive market growth over the forecast period.

The market studied consists of several major players, and the strategic product innovation by them is garnering market growth. For instance, in August 2021, Vivex Biologics, Inc., a leading regenerative medicine company, launched CYGNUS Matrix Disks, which is the latest configuration from the CYGNUS family of amniotic tissue allografts. Thus, the continuous innovation in the amniotic membrane segment is expected to drive the overall growth of the market studied.

Therefore, the factors mentioned above are attributed collectively to the studied market growth over the forecast period. However, the lack of standardized guidelines and the lack of skilled professionals are expected to hinder the market growth over the forecast period.

Amniotic membrane has several antimicrobial and biological properties in corneal surgery, as it enhances epithelialization, reinforces adhesion of basal epithelial cells, maintains epithelial phenotype, and modulates the proliferation of normal corneal, conjunctival, and limbal fibroblast. These membranes also prevent apoptosis, as well as inhibit scarring, inflammation, and neovascularization. Thus, the advantages of the amniotic membranes in the Surgical wound segment by the application are expected to drive the growth of the segment.

The rise in the hospital admission of trauma cases has increased the demand for surgeries globally. And this is anticipated to increase the demand for usage and adoption of amniotic membranes for surgical wound healing. The recent development by global market players in the segment is increasing currently, which is driving the segment growth. For instance, in July 2020, Merakris, a regenerative medicine company developing wound-healing products for skin and eyes, launched a new skin-graft alternative to help protect and heal wounds. The Amniotic membrane allograft tissue is a thin slice of human amniotic tissue from the placenta donated at the time of child delivery. It has been used for nearly a century in surgical wound healing. Thus, the advances are expected to bolster the segment growth.

Furthermore, the National Safety Council (NSC) facts and figures for injury in United States 2020 stated that bicycling accounted for about 426,000 injuries, the most among any category of sports and recreation. Exercise, with or without equipment, followed about 378,000 injuries, while ATV, moped, and minibike use with 230,000 injuries, and skateboard, scooter, and hoverboard use, with 218,00 injuries, ranked third and fourth, and these increasing number of injuries and trauma primarily require surgical wound healing which uses amniotic membranes most commonly. Thus, the increasing number of sports injuries boosted the market growth for the surgical wound segment in the forecast period.

Therefore, owing to the factors stated above, the surgical wounds segment is growing, and it is expected to have significant growth over the forecast period. Hence, driving the growth of the studied market.

North America is the largest regional market in terms of revenue, owing to high healthcare expenditure by local governments and highly developed healthcare infrastructure in United States (US) and Canada. The availability of advanced products in this region may also influence the market growth during the forecast period.

New product launches and continuous innovation by market players are anticipated to boost the market growth in the North American region. United States (US) holds a major market share in the market studied. For instance, in March 2021, TissueTech received clearance from the Food and Drug Administration (FDA) to proceed with a Phase 2 study using morselized Cryopreserved Amniotic Membrane (CAM) and Cryopreserved Umbilical Cord (CUC) Investigational New Drug (IND) TTBT01. Again, in May 2021, VIVEX Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatments, launched VIAGENEX, which is a family of amniotic allografts processed to retain the inherent mechanical properties of amniotic tissue and rich supply of extracellular matrix, growth factors, and cytokines. Thus, the rigorous product development in the countries across North America is expected to boost the amniotic membrane market growth in the region.

In addition to product launches, the number of cesarean deliveries is increasing in United States. The Centre for Disease Control and Prevention (CDC) data reviewed in September 2021 shows that the rate of low-risk cesarean delivery increased from 25.6% in 2019 to 25.9% in 2020, with increases for each race and Hispanic-origin group. Studies suggest that the use of amniotic membrane dressing is effective in reducing pain after cesarean section and can eliminate patients’ need for analgesics. Thus, the increasing product launches and cesarean delivery in the US are predicted to drive the studied market growth.

Hence, as per the factors mentioned above, the North American region is anticipated to witness dominance over the forecast period.

The amniotic membrane market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies currently dominating the market include Amnio Technology LLC, HMP Global, Inc., Human Regenerative Technologies, LLC, Katena Products. Inc., and MIMEDX, among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support